• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Urgent patient admission to Working Group for Urological Oncology (AUO) studies on metastasized renal cell carcinoma needed: prospective randomized multicenter phase II study on resection of pulmonary metastases in clear cell renal cell carcinoma ± adjuvant sunitinib therapy over 1 year (SMAT - AN 20/04 of the AUO)].

作者信息

Rexer H

机构信息

AUO, MeckEvidence, Seestraße 11, 17252 Schwarz, Deutschland.

出版信息

Urologe A. 2012 Feb;51(2):252-3. doi: 10.1007/s00120-012-2809-6.

DOI:10.1007/s00120-012-2809-6
PMID:22331073
Abstract
摘要

相似文献

1
[Urgent patient admission to Working Group for Urological Oncology (AUO) studies on metastasized renal cell carcinoma needed: prospective randomized multicenter phase II study on resection of pulmonary metastases in clear cell renal cell carcinoma ± adjuvant sunitinib therapy over 1 year (SMAT - AN 20/04 of the AUO)].急需患者加入泌尿肿瘤学工作组（AUO）关于转移性肾细胞癌的研究：一项关于透明细胞肾细胞癌肺转移灶切除±1年辅助舒尼替尼治疗（SMAT - AUO的AN 20/04）的前瞻性随机多中心II期研究。
Urologe A. 2012 Feb;51(2):252-3. doi: 10.1007/s00120-012-2809-6.
2
[AUO (Working Group on Urological Oncology) study of metastasized renal cell carcinoma: prospective randomized multicenter phase II study on resection of pulmonary metastases in clear cell renal cell carcinoma with or without adjuvant sunitinib therapy over 1 year (SMAT - AN 20/04 AUO)].
Urologe A. 2011 Jan;50(1):83-4. doi: 10.1007/s00120-010-2495-1.
3
[First-line treatment for advanced renal cell carcinoma : A phase 3, open-label, randomized study of Atezolizumab (Anti-PD-L1-Antibody) in combination with Bevacizumab versus Sunitinib in patients with untreated advanced renal cell carcinoma ("IMmotion") - AN 37/15 der AUO].
Urologe A. 2016 Sep;55(9):1242-3. doi: 10.1007/s00120-016-0188-0.
4
The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.舒尼替尼治疗计划肾切除术的转移性透明细胞肾细胞癌患者的结局。
Eur Urol. 2011 Sep;60(3):448-54. doi: 10.1016/j.eururo.2011.05.028. Epub 2011 May 17.
5
[Therapy of untreated local advanced or metastatic renal cell carcinoma. Phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, local advanced or metastatic renal cell carcinoma (CheckMate 214 - AN 36/15 of the AUO)].
Urologe A. 2015 Oct;54(10):1443-5. doi: 10.1007/s00120-015-3946-5.
6
Surgical resection of renal cell carcinoma after targeted therapy.靶向治疗后肾细胞癌的手术切除
J Urol. 2009 Sep;182(3):881-6. doi: 10.1016/j.juro.2009.05.014. Epub 2009 Jul 17.
7
Long-term response and postsurgical complete remissions after treatment with sunitinib malate, an oral multitargeted receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma.舒尼替尼治疗转移性肾细胞癌患者的长期反应和手术后完全缓解：一种口服多靶点受体酪氨酸激酶抑制剂。
Cancer Invest. 2011 May;29(4):282-5. doi: 10.3109/07357907.2011.568560.
8
Good response to second-line bevacizumab and interferon-alpha in a sunitinib-refractory patient with metastatic renal cell carcinoma.二线贝伐珠单抗联合干扰素-α治疗舒尼替尼耐药转移性肾细胞癌的疗效良好。
Anticancer Drugs. 2010 Feb;21(2):210-3. doi: 10.1097/CAD.0b013e3283340d1f.
9
Response to sunitinib in an adult patient with rhabdoid renal cell carcinoma.一名成年横纹肌样肾细胞癌患者对舒尼替尼的反应。
J Clin Oncol. 2011 Jun 20;29(18):e529-31. doi: 10.1200/JCO.2011.34.8284. Epub 2011 Apr 11.
10
Does timing of cytoreductive nephrectomy impact patient survival with metastatic renal cell carcinoma in the tyrosine kinase inhibitor era? A multi-institutional study.细胞减灭性肾切除术的时机是否会影响酪氨酸激酶抑制剂时代转移性肾细胞癌患者的生存？一项多机构研究。
Urology. 2013 Apr;81(4):805-11. doi: 10.1016/j.urology.2012.10.054. Epub 2013 Feb 13.

引用本文的文献

1
[Is surgical treatment ever indicated in metastatic renal cell carcinoma and if so, based on which scientific rationale?].[转移性肾细胞癌是否有手术治疗指征？如果有，其科学依据是什么？]
Urologe A. 2017 May;56(5):617-623. doi: 10.1007/s00120-017-0357-9.
2
Impact of metastasectomy on prognosis in patients treated with targeted therapy for metastatic renal cell carcinoma.转移灶切除术对接受靶向治疗的转移性肾细胞癌患者预后的影响。
J Cancer Res Clin Oncol. 2016 Nov;142(11):2331-8. doi: 10.1007/s00432-016-2217-1. Epub 2016 Aug 23.
3
The value of hepatic resection in metastasic renal cancer in the Era of Tyrosinkinase Inhibitor Therapy.
酪氨酸激酶抑制剂治疗时代肝切除在转移性肾癌中的价值
BMC Surg. 2016 Jul 22;16(1):49. doi: 10.1186/s12893-016-0163-0.
4
Is there a role for systemic targeted therapy after surgical treatment for metastases of renal cell carcinoma?肾细胞癌转移灶手术治疗后全身靶向治疗是否有作用？
World J Nephrol. 2015 May 6;4(2):254-62. doi: 10.5527/wjn.v4.i2.254.
5
Surgical intervention for pulmonary metastases.肺部转移瘤的外科干预。
Dtsch Arztebl Int. 2012 Oct;109(40):645-51. doi: 10.3238/arztebl.2012.0645. Epub 2012 Oct 5.